{"id":"NCT00646399","sponsor":"Biosynexus Incorporated","briefTitle":"Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis","officialTitle":"A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-03","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2008-03-28","resultsPosted":"2011-10-24","lastUpdate":"2011-10-24"},"enrollment":1579,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Staphylococcal Sepsis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Pagibaximab 50 mg/mL","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pagibaximab 50 mg/mL","type":"EXPERIMENTAL"}],"summary":"Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants. 1550 infants will be enrolled prior to 48 hours of life and will be randomized 1:1 to receive active drug or placebo on study days 0, 1, 2, 9, 16, and 23.","primaryOutcome":{"measure":"The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.","timeFrame":"35 days","effectByArm":[{"arm":"Pagibaximab","deltaMin":85,"sd":null},{"arm":"Placebo","deltaMin":79,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":284,"n":784},"commonTop":["Anaemia","Feeding Disorder Neonatal","Hyperbilirubinaemia","Gastrooesophageal Reflux Disease","Ophthalmia Neonatorum"]}}